# Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

Source: https://onco.cc/trials/nct07361484/  
OnCo record `nct07361484` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of docetaxel in lung cancer, run by BeyondSpring Pharmaceuticals Inc., not yet recruiting.

## Summary

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) is a phase 3, randomised interventional study registered as NCT07361484 by BeyondSpring Pharmaceuticals Inc., with a registry enrolment figure of 442 participants, started 2026-06-01 and due to reach its primary completion in 2029-06-01. Interventions recorded: Plinabulin; Docetaxel; Placebo (matching plinabulin placebo). Conditions listed: Non-Small Cell Lung Cancer; Non-squamous Non-Small Cell Lung Cance. Primary outcome: Overall Survival (OS). Lung eligibility wording from the registry: "Non-squamous NSCLC with EGFR, ALK, ROS and RET wild type who have been diagnosed by histopathological and/or cytological examination as being ineligible for surgical treatment and have locally advanced (stage IIIb) or metastatic (stage IV) diseases, or have recurrent and progressive disease after lo". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07361484
- Phase: 3
- Setting: A Global, Multicenter, Randomized, Double-blinded, Phase 3 Study of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer With EGFR, ALK, ROS, and RET Wild Type After Progressing on Prior Immunotherapy (Anti-PD-1/L1 Antibody) and Platinum-based Chemotherapy (DUBLIN-4)
- Sponsor: BeyondSpring Pharmaceuticals Inc.
- Enrolled: 442

## Sources

- ClinicalTrials.gov NCT07361484: https://clinicaltrials.gov/study/NCT07361484

## Connected records

- cancers: [ALK-positive non-small-cell lung cancer](https://onco.cc/cancers/alk-positive-nsclc/), [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/)
- companies: [BeyondSpring Pharmaceuticals](https://onco.cc/companies/beyondspring/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07361484.json